Literature DB >> 1375873

Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy.

T Misaki1, Y Watanabe, Y Iida, A Hidaka, K Kasagi, H Fukushima, J Konishi.   

Abstract

To elucidate the mechanism of action for intratumoral injection of immunopotentiators, infiltrating mononuclear cells and tumor necrosis factor (TNF) were assayed by immunostaining tissue samples of differentiated thyroid cancer resected with or without presurgical local application of OK-432, a streptococcal preparation. Frozen sections of resected specimens were stained with monoclonal antibodies using either a conventional or a modified immunoperoxidase method. The tumors injected with OK-432 showed increased T lymphocyte infiltration and HLA-DR expression on cancer cells as compared to the non-injected controls. Among these T cells, the CD4+ subset was more numerous than the CD8+ population. In four out of the seven cases constituting the injected group, numerous TNF-positive cells were seen in clusters or lines as well as scattered, while none of the seven cases in the control group was associated with a considerable amount of these cells. In their morphology and distribution pattern, these TNF-positive cells appeared to be of macrophage lineage. Thus local injection of OK-432 in thyroid cancer was shown to recruit T lymphocytes of predominantly the CD4+ subset and to induce in situ production of TNF, a known potent tumoricidal cytokine. The present data warrant further studies in this direction besides wider clinical intratumoral application of the reagent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375873     DOI: 10.1007/bf01741855

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Effects of rat gamma- and non-gamma-interferons on the expression of Ia antigen, growth, and differentiated functions of FRTL5 cells.

Authors:  T Misaki; D Tramontano; S H Ingbar
Journal:  Endocrinology       Date:  1988-12       Impact factor: 4.736

2.  Tumor necrosis factor: a potent mediator of macrophage-dependent tumor-cell killing.

Authors:  J L Urban; J L Rothstein; M H Shephard; H Schreiber
Journal:  Haematol Blood Transfus       Date:  1987

3.  Immunohistological phenotyping of thyroid infiltrating lymphocytes in Graves' disease and Hashimoto's thyroiditis.

Authors:  T Misaki; J Konishi; T Nakashima; Y Iida; K Kasagi; K Endo; T Uchiyama; K Kuma; K Torizuka
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

4.  Induction of interferon-gamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes.

Authors:  M Saito; T Ebina; M Koi; T Yamaguchi; Y Kawade; N Ishida
Journal:  Cell Immunol       Date:  1982-03-15       Impact factor: 4.868

5.  Induction of tumor necrosis factor by administration of OK-432 in cancer patients.

Authors:  I Kokunai; T Shimano; K Sekimoto; T Takeda; T Kobayashi; E Yayoi; A Yamamoto; T Mori
Journal:  J Clin Lab Immunol       Date:  1986-12

6.  Immunohistochemical studies on local antitumor effects of streptococcal immunopotentiator, OK-432, in human solid malignant tumors.

Authors:  A Sugenoya; N Usuda; W Adachi; G Kaneko; T Nagata; F Iida
Journal:  Arch Pathol Lab Med       Date:  1988-05       Impact factor: 5.534

7.  Augmentation of interleukin 1 and interleukin 2 production by OK-432.

Authors:  O Ichimura; S Suzuki; M Saito; Y Sugawara; N Ishida
Journal:  Int J Immunopharmacol       Date:  1985

8.  Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432).

Authors:  H Hojo; Y Hashimoto
Journal:  Gan       Date:  1981-10

9.  Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.

Authors:  H Stötter; E A Wiebke; S Tomita; A Belldegrun; S Topalian; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

10.  Immunohistochemical demonstration of cytoplasmic and membrane-associated tumor necrosis factor in murine macrophages.

Authors:  S W Chensue; D G Remick; C Shmyr-Forsch; T F Beals; S L Kunkel
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

View more
  5 in total

Review 1.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma.

Authors:  Tomoyuki Tano; Masato Okamoto; Shin Kan; Koh-Ichi Nakashiro; Shigetaka Shimodaira; Shigeo Koido; Sadamu Homma; Mitsunobu Sato; Tomonobu Fujita; Yutaka Kawakami; Hiroyuki Hamakawa
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

3.  The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer.

Authors:  Jun Liu; Xiang Liu; Fei Cui; Guoqin Chen; Yubao Guan; Jianxing He
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

4.  Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo.

Authors:  S M Dubinett; L Patrone; J Tobias; A J Cochran; D R Wen; W H McBride
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

5.  Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation.

Authors:  Tomoyuki Tano; Masato Okamoto; Shin Kan; Takashi Bando; Hiroyuki Goda; Koh-ichi Nakashiro; Shigetaka Shimodaira; Shigeo Koido; Sadamu Homma; Tomonobu Fujita; Mitsunobu Sato; Naomi Yamashita; Hiroyuki Hamakawa; Yutaka Kawakami
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.